BeOne Medicines Wins FDA Priority Review for BRUKINSA Combination
The FDA granted Priority Review to BeOne Medicines' BRUKINSA combination for first-line mantle cell lymphoma.
The FDA granted Priority Review to BeOne Medicines' BRUKINSA combination for first-line mantle cell lymphoma.